MARKET

CERC

CERC

Cerecor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.500
-0.010
-0.40%
Opening 10:30 04/23 EDT
OPEN
2.500
PREV CLOSE
2.510
HIGH
2.519
LOW
2.430
VOLUME
76.39K
TURNOVER
--
52 WEEK HIGH
4.500
52 WEEK LOW
1.970
MARKET CAP
222.76M
P/E (TTM)
-2.4819
1D
5D
1M
3M
1Y
5Y
--Maxim Upgrades Cerecor to Buy from Hold, Sets $7 Price Target
MT Newswires · 2d ago
OCGN, RRD, ERII and GOGL among premarket gainers
Alterity Therapeutics (ATHE) +22%.Welbilt (WBT) +19% on being acquired by The Middleby Corp.Sierra Metals (SMTS) +12%.Williams Industrial Services (WLMS) +12%.Uxin Limited (UXIN) +9%.inTEST Corporation (INTT) +8%.Ocugen (OCGN) +7%.Energy Recover (ERII) +7%...
Seekingalpha · 2d ago
DJ Cerecor Initiated at Buy by Jefferies
Dow Jones · 3d ago
DJ Cerecor Price Target Announced at $4.00/Share by Jefferies
Dow Jones · 3d ago
--Jefferies Initiates Cerecor at Buy with $4 Price Target
MT Newswires · 3d ago
Cerecor shares rise 5% as mAb shows promise in small COVID-19 trial
CERC-002, a monoclonal antibody (mAB) from Cerecor (CERC), reduced respiratory failure and death in a small trial of hospitalized COVID-19 patients.Results, published as a preprint in medRxiv and not yet
Seekingalpha · 04/07 16:25
Cerecor Inks New Global License Agreement With Kyowa Kirin For CERC-002
Cerecor Inc's (NASDAQ: CERC) wholly-owned subsidiary, Aevi Genomic Medicine LLC, has 
Benzinga · 03/29 12:33
Cerecor inks CERC-002 licensing deal with Kyowa Kirin, shares up 6%
Cerecor's (CERC) wholly-owned subsidiary, Aevi Genomic Medicine (GNMX) has entered into an expanded agreement with Kyowa Kirin (KYKOF), for exclusive worldwide rights to develop, manufacture and commercialize CERC-002 monoclonal antibody
Seekingalpha · 03/29 11:14
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CERC. Analyze the recent business situations of Cerecor through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CERC stock price target is 10.60 with a high estimate of 24.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 85
Institutional Holdings: 50.12M
% Owned: 56.25%
Shares Outstanding: 89.10M
TypeInstitutionsShares
Increased
23
1.37M
New
8
83.87K
Decreased
12
1.22M
Sold Out
7
162.77K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.20%
Pharmaceuticals & Medical Research
+0.22%
Key Executives
Chairman/Director
Sol Barer
Chief Executive Officer
Mike Cola
Chief Executive Officer/Director
Michael Cola
Chief Financial Officer/Treasurer
Schond Greenway
Chief Accounting Officer
Christopher Sullivan
Other
Jamie Harrell
Other
Garry Neil
Other
Jeff Wilkins
Director
Suzanne Bruhn
Director
Joseph Miller
Independent Director
Steven Boyd
Independent Director
Phil Gutry
Independent Director
Gilla Kaplan
Independent Director
Magnus Persson
No Data
About CERC
Cerecor, Inc. is a biopharmaceutical company. The Company is focused on development and commercialization of treatments for pediatric and orphan diseases. Its pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The Company is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody which is developed for autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma. CERC-006 is an mTORC1/2 inhibitor which is developed as a treatment for Lymphatic Malformations (LM). CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes), monoclonal antibody is developed as a treatment for Pediatric Crohn's Disease.

Webull offers kinds of Cerecor Inc stock information, including NASDAQ:CERC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CERC stock methods without spending real money on the virtual paper trading platform.